




## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 : <b>G01N 33/543, 33/547, C12Q 1/68</b>		<b>A1</b>	(11) International Publication Number: <b>WO 95/16204</b>
			(43) International Publication Date: <b>15 June 1995 (15.06.95)</b>
(21) International Application Number: <b>PCT/GB94/02680</b>		(81) Designated States: CA, JP, US, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).	
(22) International Filing Date: <b>7 December 1994 (07.12.94)</b>		<b>Published</b> <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>	
(30) Priority Data: <b>9325100.7 7 December 1993 (07.12.93) GB</b>			
(71) Applicant (for all designated States except US): <b>UNIVERSITY COURT OF THE UNIVERSITY OF GLASGOW [GB/GB]; University Avenue, Glasgow G12 8QQ (GB).</b>			
(72) Inventors; and (75) Inventors/Applicants (for US only): <b>MORGAN, Hywel [GB/GB]; 3 Auldea Road, Beith, Ayrshire KA15 2BZ (GB). PRITCHARD, David, John [GB/GB]; 27 Hillhead Street, Glasgow G12 8PX (GB). COOPER, Jonathon, Mark [GB/GB]; 32 Duncan Avenue, Glasgow G14 9NH (GB).</b>			
(74) Agent: <b>MURGITROYD &amp; COMPANY; 373 Scotland Street, Glasgow G5 8QA (GB).</b>			

(54) Title: **SURFACE-PATTERNED DEVICE**

## (57) Abstract

There is described a device which has a surface coated with a biomolecule in a pre-determined pattern. The molecule is attached to the surface via a photosensitive binding moiety itself attached to the surface via a linking moiety. Preferably the linking moiety is avidin or a derivative thereof and the photosensitive binding moiety is photobiotin or a derivative thereof. The pattern of binding of the biomolecule is determined by the selective irradiation of non-irradiation of the photosensitive binding moiety. In a preferred embodiment two or more different ligands are bound to the surface in a pre-determined pattern. The device according to the invention may be of use in multi-analyte sensors in molecular electronics, in directional propagation of cell growth and in altering the behaviour of cells. The device may also be used to bind nucleotides which are subsequently manipulated or used as a probe or template.



**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

1     "SURFACE-PATTERNED DEVICE"

2

3     The present invention relates to a device wherein  
4     molecules are attached to a surface in a pre-determined  
5     pattern. A process for producing such a device is also  
6     disclosed.

7

8     Various applications in technology require a device to  
9     have a surface which is coated with a molecule, such as  
10    an organic molecule. Generally, a uniform layer of the  
11    molecule required is bound to the surface. Optionally  
12    the bound molecule may then be used to attach other  
13    molecules to the surface.

14

15    Surfaces coated with biomolecules in this way have many  
16    applications, for example in assays or diagnostic  
17    tests. One popular assay is an immunoassay, involving  
18    the use of antibodies to selectively bind to an antigen  
19    of interest. Frequently, the antibody may be bound to  
20    a surface giving a convenient diagnostic device. Other  
21    applications where binding biomolecules to a surface is  
22    useful includes the separation and purification of  
23    biomolecules.

24

1 GB-A-2141544 discloses a method of binding biomolecules  
2 to a surface in a particular pattern. The biomolecules  
3 are bound via a photosensitive intermediate organic  
4 molecule, such as N-(4-azido-2-nitrophenyl)-1,3-  
5 diaminopropane. By using a mask, the photactivatable  
6 organic molecule is light activated in specific areas  
7 only and the biomolecule is subsequently only able to  
8 bind to those areas.

9  
10 The process of GB-A-2141544 may result in non-specific  
11 binding, since biomolecules other than the one of  
12 interest may also be bound to the activated  
13 photosensitive intermediate resulting in a poor quality  
14 product. Problems in binding the molecules of interest  
15 may also occur due to steric restrictions. Further,  
16 the process described in GB-A-2141544 is dependent upon  
17 covalent attachment of the photosensitive intermediate  
18 organic molecule to the surface.

19  
20 The present invention seeks to overcome the problems  
21 encountered in the prior art and to provide patterning  
22 of molecules upon a surface in a precise manner.

23  
24 In one aspect, the present invention provides a device  
25 having a surface, said surface having a ligand bound  
26 thereto in a pre-determined pattern, the binding of  
27 said ligand being determined by the irradiation or non-  
28 irradiation of a photosensitive binding moiety attached  
29 to said surface via a linking moiety.

30  
31 The coated surface of the device is preferably capable  
32 of producing measurable change. The change may be  
33 detected by any suitable means, for example optically,  
34 spectrophotometrically, piezoelectrically, calori-  
35 metrically or by measuring magnetic field strength.

1 Desirably, the device of the present invention has a  
2 surface on which at least two different ligands are  
3 arranged thereon in a pre-determined manner.  
4

5 The linking moiety must be able to be uniformly bound  
6 to the surface of interest. Selection of the technique  
7 to bind the linking moiety may thus depend upon the  
8 chemical character of the surface. Furthermore the  
9 linking moiety preferably has the function of  
10 preventing or reducing non-specific binding. The  
11 linking moiety may also be of utility in spacing out  
12 the binding moiety to avoid steric hindrance problems  
13 in binding the ligand. Preferably the linking moiety  
14 may be orientated in a particular manner on the  
15 surface.  
16

17 The term "functional equivalent" is used herein to  
18 refer to any modified version of a moiety which retains  
19 the basic function of the moiety in its unmodified  
20 form. As an example, it is well-known that certain  
21 alterations in amino acid or nucleic acid sequences may  
22 not affect the protein encoded by that molecule or the  
23 function of the protein. It is also possible for  
24 deleted versions of a molecule to perform a particular  
25 function as well as the original molecule.  
26 Even where an alteration does affect whether and to  
27 what degree a particular function is performed, such  
28 altered molecules are included within the term  
29 "functional equivalent" provided that where the  
30 function concerned is required for production of the  
31 device according to the invention then this function is  
32 performed sufficiently to render the device operational  
33 within the degree of accuracy required for the ultimate  
34 end use of the device.  
35

1 Conveniently, the linking moiety is itself an organic  
2 molecule. The linking moiety may be a macromolecule,  
3 for example a macromolecule having a molecular weight  
4 of at least 500Da, or the linking moiety may be a  
5 biomolecule such as polypeptides or proteins, mono-,  
6 di- or poly-saccharides, or functional equivalents  
7 thereof. However, non-biological molecules are not  
8 excluded and examples include polymers and other  
9 organic molecules. Preferably, the linking moiety is a  
10 polypeptide or protein, and particularly preferred  
11 examples include avidin, streptavidin or functional  
12 equivalents thereof.

13  
14 The linking moiety may be bound to the surface by any  
15 type of association, including non-covalent and  
16 covalent binding, ionic interaction and intermolecular  
17 associations such as hydrogen bonding, and Van der  
18 Waals attractions. Non-covalent interactions may be  
19 preferred in certain applications.

20  
21 Alternatively, the linking moiety may be attached to  
22 the surface by physical entrapment.

23  
24 It may be desirable in certain applications to attach  
25 the linking moiety to the surface so that substantially  
26 all of the linking moieties are orientated in the same  
27 or similar direction on at least part of the surface.

28  
29 It is not necessary for the linking moiety to be  
30 directly attached to the surface, and in some  
31 circumstances the surface may be coated (optionally  
32 several times) before the linking moiety is attached to  
33 a layer thereof, usually the uppermost layer. Where  
34 the linking moiety is attached to the surface by  
35 entrapment in a carrier substance, it may be desirable

1 to coat the surface with an admixture of linking moiety  
2 in the carrier substance, the carrier adhering to the  
3 surface and physically entrapping the linking moiety.

4  
5 The binding moiety may be any photosensitive entity  
6 which binds to said linking moiety. As an example, the  
7 binding moiety may be based on a biomolecule, such as a  
8 protein, polypeptide, mono-, di- or poly-saccharide,  
9 polynucleic acid and the like, or functional  
10 equivalents thereof. Also suitable as the binding  
11 moiety are small biological or non-biological molecules  
12 such as a photosensitive derivatives of biotin (2-keto-  
13 3,4-imidazolido-2-tetrahydrothiophen-n-valeric acid).  
14 A suitable photosensitive derivative of biotin is the  
15 molecule (N-(4-azido-2-nitrophenyl)-N'-(N-d-biotinyl-3-  
16 aminopropyl)-N'-methyl-1,3-propanediamine), commonly  
17 known as "photobiotin". Alternatively, the binding  
18 moiety may be any protein or polypeptide (or functional  
19 equivalent thereof) able to bind to the specific ligand  
20 of interest. In this regard, mention may be made of  
21 enzymes and antibodies which are suitable for use as  
22 said binding moiety. In particular, photosensitive  
23 antibodies (for example monoclonal antibodies) or  
24 biotin are preferred.

25  
26 It is essential that the binding moiety is  
27 photosensitive, that is to say that the binding moiety  
28 is sensitive to irradiation. The term "photosensitive"  
29 is used herein to indicate that the binding moiety is  
30 altered (physically and/or chemically) by exposure to  
31 electro-magnetic radiation. Preferably, the binding  
32 moiety is activated by electro-magnetic irradiation.  
33 The binding moiety may be irradiated by any type of  
34 light including visible light, UV light and infra-red  
35 light.

1 Generally, irradiation of said binding moiety occurs in  
2 pre-selected areas to impose the desired pattern  
3 thereon. Selective irradiation may be achieved by any  
4 known method, but one convenient way is to superimpose  
5 a mask or screen of irradiation-absorbing or reflecting  
6 material over the surface. The shape of the mask is  
7 transferred into the surface by the alteration of  
8 binding moieties exposed to the radiation. Other means  
9 of selectively altering binding moieties include the  
10 use of focused radiation or irradiation sources such as  
11 lasers.

12  
13 In one embodiment, irradiation causes activation of the  
14 photosensitive binding moieties exposed to the  
15 radiation. Only the activated binding moieties are  
16 able to bind to the ligand. In this embodiment the  
17 pattern of ligand binding corresponds to those areas  
18 exposed to irradiation.

19  
20 In another embodiment, irradiation alters the exposed  
21 binding moieties. Only the binding moieties which have  
22 not been altered by such exposure (that is, only the  
23 binding moieties which were not irradiated and which  
24 retain their original configuration), are able to bind  
25 to the ligand. In this embodiment the pattern of  
26 irradiation corresponds to areas not bound by ligand.

27  
28 The binding moiety will usually be in its  
29 photosensitive form when initially contacted with the  
30 linking moiety. However this is not essential and  
31 under certain circumstances it may be more convenient  
32 to photosensitize a form of the binding moiety in situ  
33 after attachment to the linking moiety has taken place.

34  
35 The ligand can be any molecule, including proteins,




1 polypeptides, electron mediators, amino acids, sugars,  
2 polysaccharides, nucleic acids and other organic or  
3 inorganic molecule (and functional equivalents  
4 thereof). The ligand may itself be able to bind to a  
5 further moiety. For example, the ligand may be an  
6 antibody (especially a monoclonal antibody) which may  
7 be bound via its Fc region to the binding moiety.  
8 Conveniently, the ligand may be a difunctional antibody  
9 (especially a monoclonal antibody), that is an antibody  
10 having the ability to bind two different haptens  
11 separately. Alternatively, the ligand may be an enzyme  
12 (or a functional equivalent thereof) or a polynucleic  
13 acid.

14  
15 In a further embodiment, it is possible to bind two or  
16 more different ligands onto the binding moiety in  
17 distinct areas. This can be achieved, for example, by  
18 irradiation of the surface only in those areas where  
19 the first ligand is to be bound. The first ligand is  
20 then brought into contact with the irradiated surface,  
21 allowed to bind thereto and any excess ligand washed  
22 off. The surface may then be selectively exposed to  
23 radiation a second time, once the first ligand has  
24 bound, thus activating a second selection of binding  
25 moieties. A second ligand may be bound to the binding  
26 moieties so activated. This process may be repeated as  
27 many times as required for each set of ligands to be  
28 selectively bound to the surface in a pre-determined  
29 way.

30  
31 It is possible to coat the binding moieties not reacted  
32 to ligand by use of a blocking moiety. Suitable  
33 blocking proteins are known in the art, but mention may  
34 be made of milk proteins such as casein, TRIS<sup>TM</sup> buffer,  
35 or serum albumins such as HSA or BSA.

1 In a preferred embodiment, the linking moiety may be  
 2 the tetrameric proteins avidin, streptavidin,  
 3 functional equivalents or mixtures thereof. Certain  
 4 avidins and streptavidins have low non-specific binding  
 5 properties thus eliminating non-specific adsorption.  
 6 Any other protein or polypeptide with this  
 7 characteristic will be suitable as a linking moiety in  
 8 the present invention. It is especially preferred if  
 9 the binding moiety used therewith is a photosensitive  
 10 analogue of biotin (vitamin H) which binds to avidin  
 11 and streptavidin with an association constant of  $10^{15} \text{M}^{-1}$ .  
 12 The photosensitive analogue of biotin may be  
 13 photobiotin (ie N-(4-azido-2-nitrophenyl)-N'-(N-d-  
 14 biotinyl-3-aminopropyl-N'-methyl-1,3-propanediamine).  
 15 Photobiotin contains an arylazide group which is stable  
 16 in the dark, but upon exposure to ultra-violet or blue  
 17 light (having a wavelength of 340-375nm) generates  
 18 highly reactive aryl nitrene group which may bind other  
 19 molecules. The photobiotin may incorporate a spacer  
 20 moiety to reduce steric hindrance on binding the  
 21 ligand. The structure of the spacer-photobiotin  
 22 molecule is shown in Formula 1 below:



1 The surface to be coated may be any convenient type,  
2 including silicon, silicon nitride, silicon dioxide,  
3 glass, quartz, metals, metal oxides, polymers including  
4 nitrocellulose and nylon, and mixtures thereof.  
5 Preferably, the surface is gold, platinum, silicon or  
6 silicon oxide, dioxide or nitride and mixtures thereof.

7  
8 In a preferred embodiment, the present invention  
9 provides a device having a surface, said surface having  
10 a ligand arranged thereon in a pre-determined pattern,  
11 the binding of said ligand being determined by the  
12 irradiation of a photosensitive biotin binding moiety  
13 attached to the surface via an avidin linking moiety.  
14 The ligand may desirably be an enzyme, for example  
15 glucose oxidase, an immunoglobulin, for example an  
16 antibody, or a hormone, for example human  
17 gonadotrophins.

18  
19 The precise binding of a ligand in a pre-determined  
20 pattern has many applications. One particularly  
21 promising aspect is the use of a surface according to  
22 the invention as part of a multi-analyte sensor, in  
23 particular a multi-analyte immunosensor. The present  
24 invention is particularly suited to this application  
25 since each ligand type can be located on the surface  
26 with accuracy, eliminating "cross-talk" in the sensor.

27  
28 There has been considerable interest over the last  
29 decade in the development of amperometric immunoassay,  
30 primarily as the technique has the potential to combine  
31 the advantages of using a sensitive enzyme label with a  
32 convenient and safe format (see Frew et al, Anal Chem  
33 59: 933A-944A (1987)). Although there is now an  
34 extensive literature in the development of such assays  
35 for both clinical and environmental analysis (see

1 "Biosensors", Hall, Wiley (1990)), to date there has  
2 been no published description of the fabrication of a  
3 true multi-analyte amperometric biosensor, in which  
4 more than one high molecular weight species is measured  
5 simultaneously by a single device. Of the existing  
6 multi-analyte immunosensors, commercial devices that  
7 have been produced are qualitative optical assays  
8 (based upon agglutination) for low molecular weight  
9 analytes (eg the Triage™ and Advisor™ systems (see  
10 Buechler et al, Clin Chem 38: 1678-1684; and Parsons et  
11 al Clin Chem 39: 1899-1903 (1993)) for detecting drugs  
12 of abuse). Such systems are unsuitable for  
13 quantitative analysis.

14  
15 The use of simultaneous multi-analyte immunoassay is  
16 required in a number of clinical situations including  
17 the measurement of hormones related with thyroid  
18 function and the measurement of gonadotrophins for the  
19 investigation of infertility. An example where such an  
20 assay would be useful is for the measurement of  
21 follicle stimulating hormone (FSH) and luteinising  
22 hormone (LH), which can be used as a "fertility test"  
23 in women, or to differentiate between primary and  
24 secondary hypogonadism. FSH and LH are both  
25 glycoprotein hormones, with relative molecular masses  
26 of approximately 34,000 and 28,500 respectively.  
27 Circulating gonadotrophin concentrations are widely  
28 monitored in diagnosis and treatment of infertility, as  
29 well as in developmental disorders. For example, in  
30 primary hypogonadism, the concentrations of  
31 gonadotrophins increase in a process controlled by  
32 negative feedback, whereas in secondary hypogonadism  
33 low levels of FSH and LH are the cause of the disorder.  
34 A particular situation where the use of an immunosensor  
35 for the measurement of gonadotrophins is likely to be

1     beneficial, is for *in vitro* fertilisation procedures  
2     where the rapid measurement of gonadotrophins is  
3     important.  
4

5     The major challenge for designing a multi-analyte  
6     immunosensor is in developing a technique for  
7     patterning of antibodies at discrete transducer sites,  
8     ie a method which enables immunologically active IgG to  
9     be selectively positioned at particular sites whilst  
10    avoiding problems associated with non-specific binding  
11    at other sites. Previously a number of methods for  
12    immobilising antibodies in such "patterns" on a surface  
13    have been reported, although their potential  
14    applicability to biosensor technology has been limited  
15    by the number of functional proteins that can be  
16    patterned and/or by non-specific binding of protein to  
17    undesignated areas of the sensor or its surround (see  
18    Britland et al, *Biotechnol. Prog.* 8: 155-160 (1992);  
19    Bhatia et al, *Anal Biochem*, 208: 197-205 (1993);  
20    Connolly, *Trends in Biotechnology* 12: 123-127 (1994)).  
21

22    The device according to the invention may also be used  
23    to selectively deposit molecules onto a surface in  
24    ordered arrays for use in molecular electronics. Thus,  
25    groups of molecules may be positioned precisely with  
26    respect to other groups of molecules, or to electronic  
27    structures in order to build up functional molecular  
28    architectures. As is the case for the design of a  
29    diagnostic device, a variety of different transducer  
30    materials may be used as immobilisation substrates, and  
31    the design of arrays that do not exhibit cross-talk is  
32    of great importance. Such devices could be used for  
33    design of bioelectronic memory cells, or more  
34    elaborately, in biological computing.  
35

1 A further application of this invention is in a device  
2 for the directional propagation of an individual cell,  
3 (eg nerve cells or their neurites) on a patterned  
4 substrate. In this case, the essential prerequisites  
5 are the same as for the design of a diagnostic device,  
6 in so much as it is desirable to position organic,  
7 inorganic or biological molecules (eg nerve growth  
8 factor) onto a pre-defined substrate with no  
9 interference from non-specific adsorption. The  
10 patterned molecules will act as a chemotactic or  
11 topological template for guidance of the cell, which  
12 will grow preferentially in a given direction  
13 determined by the pattern. Particularly important  
14 applications are the manufacture of devices either to  
15 control endothelial cell growth for wound healing, or  
16 to control nerve cell growth to promote regeneration.

17  
18 In addition, it may be desirable to use a patterning  
19 technique to alter the behaviour of many cells. For  
20 example, by coating appropriate molecules onto a  
21 surface, it will be possible to differentially promote  
22 or prevent cell growth on the outer surface of a  
23 miniature sensor in order to enhance the  
24 biocompatibility properties of the device.

25  
26 The device according to the present invention is also  
27 of utility as a matrix for binding nucleotides, for  
28 example DNA or RNA molecules. The nucleotides may be  
29 single stranded or double stranded. The nucleotide  
30 bound to the device may be used as a probe (for example  
31 for nucleotides having a complementary sequence or to  
32 bind nucleic acid binding proteins) or may be  
33 manipulated by chemical reactions or by genetic  
34 engineering techniques. A nucleotide bound to the  
35 device according to the invention may be used as a

1     template in a polymerase chain reaction (PCR) method.

2

3     In a further aspect, the present invention provides a  
4     process for forming a surface having a ligand bound  
5     thereto in a pre-determined pattern, said process  
6     comprising the following steps:

7

8     i)    binding a linking moiety to a coated or uncoated  
9           surface;

10

11    ii)   binding a photosensitive binding moiety to said  
12          linking moiety;

13

14    iii)  selectively exposing said photosensitive binding  
15          moiety to irradiation in a pre-determined pattern;

16

17    iv)   exposing said binding moiety to said ligand and  
18          allowing the ligand to bind to said binding moiety  
19          in accordance with the irradiation exposure;

20

21    v)    optionally removing excess ligand by washing;

22

23    vi)   optionally exposing said ligand to a further  
24          molecule capable of binding thereto; and

25

26    vii)  optionally repeating steps iii) and iv) with a  
27          different ligand.

28

29     Figures 1 to 3 are schematic representations of the  
30     process of the present invention.

31

32     Figures 4 to 7 are graphs showing the results of  
33     Example 7.

34

35     Figure 4 is a graph showing the electrochemical

1 response (nA) of the disposable multi-analyte sensor to  
2 FSH ( $\text{U l}^{-1}$ ) in buffer. There is a linear response at the  
3 FSH electrode (o) to FSH over the concentration range  
4 0-100  $\text{U l}^{-1}$  and there is minimal response at the LH  
5 electrode (•) to FSH, indicating low non-specific  
6 binding.

7  
8 Figure 5 is a graph showing the electrochemical  
9 response (nA) of the disposable multi-analyte sensor to  
10 LH ( $\text{U l}^{-1}$ ) in buffer. There is a linear response at the  
11 LH electrode (•) to LH over the concentration range 0-  
12 100  $\text{U l}^{-1}$  and there is minimal response at the FSH  
13 electrode (o) to LH.

14  
15 Figure 6 is a graph showing results for FSH in serum,  
16 obtained using the multianalyte immunosensor (as  
17 described in Example 7), plotted against those obtained  
18 using an established DELFIA technique. Each sample was  
19 measured in triplicate and the error bars represent two  
20 standard deviations around the mean.

21  
22 Figure 7 is a graph showing results for LH in serum,  
23 obtained using the multianalyte immunosensor (as  
24 described in Example 7), plotted against those obtained  
25 using an established DELFIA technique. Each sample was  
26 measured in triplicate and the error bars represent two  
27 standard deviations around the mean.

28  
29 A diagrammatic representation of an example of the  
30 process according to the invention is shown in Figures  
31 1 and 2 and demonstrates the patterning of three  
32 species using avidin as the linking moiety and  
33 photobiotin as the binding moiety, and exposing defined  
34 areas of the surface to light by the use of a mask.

35



1 Initially, avidin is coated over the entire surface  
2 (Step a), photobiotin is then added and binds to the  
3 avidin (Step b). Exposure of selected areas to light  
4 results in cleavage of the photobiotin molecule (Step  
5 c), and when the first ligand to be immobilised is  
6 added, specific immobilisation occurs due to reaction  
7 with the exposed aryl nitrene group of the cleaved  
8 photobiotin.

9  
10 After washing off any unbound material, the procedure  
11 is repeated with the second ligand to be immobilised  
12 (Steps e to g). Again any unbound material is washed  
13 off, and the entire surface is then exposed to light  
14 (Step h), and a blocking species may be added whose  
15 function is to bind to all of the previously unoccupied  
16 photobiotin molecules and so block further reactions  
17 involving the photobiotin molecule (Step i). Any  
18 excess of this blocking species is washed off leaving  
19 the surface with the desired pattern of molecules on  
20 its surface (Step j).

21  
22 Figure 3 is a schematic representation of the  
23 immobilisation procedure: (a) Avidin with photobiotin  
24 immobilised onto a surface; (b) exposure of selected  
25 areas to light through a mask results in activation of  
26 the photobiotin molecule, specifically immobilising any  
27 protein in the solution; (c) unbound material is  
28 removed by washing, and the procedure repeated with a  
29 second protein; (d) the entire surface is exposed to  
30 light, and a blocking molecule bound to all unreacted  
31 photobiotin groups.

32  
33 The invention will now be further illustrated by the  
34 following, non-limiting examples:

1     Example 1

2

3     (1)   Light dependent coupling of glucose oxidase to a  
4           gold surface.

5

6     Avidin D<sup>TM</sup> (Vector Products Ltd, USA) was immobilised on  
7     to two identical gold electrodes by placing the  
8     electrodes in 5ml of a 0.2mg ml<sup>-1</sup> solution of Avidin D  
9     in phosphate buffered saline pH 7.4 (PBS) for one hour  
10    at ambient temperature. After extensive rinsing with  
11    PBS the electrodes were then incubated in 5ml of a 10µg  
12    ml<sup>-1</sup> solution of long arm photobiotin in PBS for 20  
13    minutes under dark room conditions. After extensive  
14    rinsings with PBS each electrode had 50µl of identical  
15    solutions of glucose oxidase in PBS placed onto it, one  
16    electrode was retained in dark room conditions whilst  
17    the other was exposed to light from a high pressure  
18    mercury vapour lamp for 15 minutes. After extensively  
19    rinsing both electrodes with PBS under dark conditions,  
20    50µl of a 10 mg ml<sup>-1</sup> solution of bovine serum albumin in  
21    PBS was added to each electrode and they were exposed  
22    to light from a high pressure mercury vapour lamp for  
23    15 minutes.

24

25    (2)   Assay for glucose oxidase activity

26

27    An amperometric assay was performed using the modified  
28    gold surface as a working electrode, with a Ag/AgCl  
29    electrode as a reference and a bare platinum flag as a  
30    counter electrode. Chronoamperometry was performed in  
31    working solutions containing 0 mM and 100 mM glucose  
32    solutions in 15mls PBS. The solutions also  
33    contained 25 mM KCl as the electrolyte. Initially, the  
34    working electrode was poised at a potential of 0V for  
35    300 seconds after which the potential was stepped to

1 650mV for 120 seconds during which time the current was  
2 monitored.

3

4 Current 30 seconds after  
5 application of 650 mV potential  
6  $\mu\text{A}$

7

8 Electrode exposed Electrode  
9 to light kept in dark

10

11 0 mM glucose 0.086 0.089

12 100 mM glucose 0.358 0.084

13

14 Example 2

15

16 (1) Light dependent coupling of an antibody to a gold  
17 surface

18

19 Avidin D and photobiotin were immobilised onto two gold  
20 electrodes according to the process of Example 1.

21 After extensive rinsing with PBS each electrode had  
22 50 $\mu\text{l}$  of identical solutions of rabbit anti-rat IgG in  
23 PBS placed onto it and they were exposed to light from  
24 a high pressure mercury vapour lamp for 15 minutes.

25

26 (2) Assay for antibody activity

27

28 One of the electrodes was placed in 5 ml of 10 $\mu\text{g ml}^{-1}$   
29 rat IgG in PBS for 60 minutes, whilst the other was  
30 placed in 5 ml of 10 $\mu\text{g ml}^{-1}$  rabbit IgG for 60 minutes.  
31 Following this both electrodes were extensively washed  
32 with PBS and were incubated in 5 ml of a solution of  
33 20 $\mu\text{g ml}^{-1}$  horseradish peroxidase labelled rabbit anti-  
34 rat IgG ambient temperature for 60 minutes. An  
35 amperometric assay was performed using the modified

1 gold surface as a working electrode, with a Ag/AgCl  
2 electrode as the reference and a bare platinum flag as  
3 a counter electrode. After thorough rinsing the  
4 electrodes were placed in 15ml of 25mM KCL, 10mM  
5 hydrogen peroxide, 1mM ferrocene monocarboxylic acid  
6 and a potential of 0V was applied for 10 seconds  
7 followed by 320 mV for 120 seconds during which time  
8 the current was monitored.

9		
10	Sample	Current 30 seconds after
11		application of a 320 mV
12		potential $\mu$ A
13		
14	Electrode 1 in PBS	0.079
15	Electrode 2 in PBS	0.083
16	Electrode 1 + Rat IgG	0.243
17	Electrode 2 + Rabbit IgG	0.084

18

19 Example 3

20

21 (1) Light dependent coupling of a protein to a silicon  
22 oxide surface

23

24 A wafer of silicon dioxide was immersed in a 1%  
25 solution of 1,3-trimethoxysilylpropylethylene diamine  
26 in 95% ethanol 5% distilled water for 120 seconds.  
27 After removing the wafer from this solution it was  
28 rinsed briefly in 95% ethanol 5% distilled water before  
29 being heated at 120°C for 30 minutes. The wafer was  
30 immersed in a 2% solution of gluteraldehyde in PBS for  
31 15 minutes, and then in a solution of 40mM sodium  
32 cyanoborohydride, containing 0.2mg ml<sup>-1</sup> Avidin D in PBS  
33 for 30 minutes at ambient temperature. After extensive  
34 rinsing with PBS the wafer was then incubated in 5ml of  
35 a 10 $\mu$ g ml<sup>-1</sup> solution of long arm photobiotin in PBS for

1 20 minutes under dark room conditions. After extensive  
2 rinsing with PBS the wafer was covered with a solution  
3 of  $10\mu\text{g ml}^{-1}$  rabbit IgG and exposed to light from a high  
4 pressure mercury vapour lamp for 15 minutes through a  
5 chrome mask patterned with grids having lines of width  
6  $2\mu\text{m}$ ,  $4\mu\text{m}$ ,  $6\mu\text{m}$  and  $8\mu\text{m}$  in equal mark space ratio. After  
7 extensive rinsing with PBS the wafer was covered with a  
8 solution of  $10\text{mg ml}^{-1}$  bovine serum albumin and was  
9 exposed to light from a high pressure mercury vapour  
10 lamp for 15 minutes.

11

## 12 (2) Assessment of protein patterning

13

14 The wafer was covered with a solution of  $10\mu\text{g ml}^{-1}$  TRITC  
15 labelled goat anti-rabbit IgG, for 60 minutes at  
16 ambient temperature. After washing in PBS at distilled  
17 water the sample was dried in a stream of nitrogen and  
18 examined using fluorescent microscopy. Areas of  
19 fluorescence were observed which matched the mask that  
20 had been used. Features as small as  $4\mu\text{m}$  could be  
21 resolved.

22

## 23 Example 4

24

### 25 (1) Light dependent coupling of two proteins to a 26 silicon dioxide surface

27

28 Avidin D and photobiotin were immobilised onto the  
29 silicon dioxide surface as described in Example 3.  
30 After extensive rinsing with PBS the wafer was covered  
31 with a solution of  $10\mu\text{g ml}^{-1}$  rabbit IgG and exposed to  
32 light from a high pressure mercury vapour lamp for 15  
33 minutes through a chrome mask patterned with a  $25\mu\text{m}$   
34 grid in equal mark space ratio. After extensive  
35 rinsing with PBS the wafer was covered with a solution

1 of 10 $\mu$ g ml<sup>-1</sup> rat IgG and exposed to light from a high  
2 pressure mercury vapour lamp for 15 minutes through the  
3 same mask used in Example 3 that had been turned  
4 through an angle of 90°. After extensive rinsing with  
5 PBS the wafer was covered with a solution of 10mg ml<sup>-1</sup>  
6 bovine serum albumin and was exposed to light from a  
7 high pressure mercury vapour lamp for 15 minutes.

8  
9 (2) Assessment of protein patterning

10  
11 The wafer was covered with a solution of 10 $\mu$ g ml<sup>-1</sup> TRITC  
12 labelled goat anti-rabbit IgG, for 60 minutes at  
13 ambient temperature. After extensive rinsing with PBS  
14 the wafer was covered with a solution of 10 $\mu$ g ml<sup>-1</sup> FITC  
15 labelled rabbit anti-rat IgG, for 60 minutes at ambient  
16 temperature. After washing in PBS and distilled water  
17 the sample was dried in a stream of nitrogen and  
18 examined using a fluorescent microscope. Unbroken  
19 lines of red fluorescence corresponding to the  
20 immobilised rabbit IgG were observed, and lines of  
21 green fluorescence corresponding to the immobilised rat  
22 IgG were observed running perpendicular to the red  
23 lines. Where the fluorescent lines crossed the green  
24 lines due to rat IgG were discontinued.

25  
26 Example 5

27  
28 (1) Light dependent coupling of a protein to a glass  
29 surface

30  
31 A glass wafer was immersed in a 1% solution of 1,3-  
32 trimethoxysilylpropylethylene diamine in 95% ethanol 5%  
33 distilled water, pH adjusted to 5.0 with glacial acetic  
34 acid for 30 seconds. After removing the wafer from  
35 this solution it was rinsed briefly in 95% ethanol 5%

1 distilled water before being heated at 120°C for 30  
2 minutes. The wafer was immersed in a 2% solution of  
3 glutaraldehyde in PBS for 15 minutes, and then in a  
4 solution of 40mM sodium cyanoborohydride, 0.2mg ml<sup>-1</sup>  
5 Avidin D in PBS for 30 minutes at ambient temperature.  
6 After extensive rinsing with PBS the wafer was then  
7 incubated in 5ml of a 10µg ml<sup>-1</sup> solution of long arm  
8 photobiotin in PBS for 20 minutes under dark room  
9 conditions. After extensive rinsing with PBS the wafer  
10 was covered with a solution of 10µg ml<sup>-1</sup> rat IgG and  
11 exposed to light from a high pressure mercury vapour  
12 lamp for 15 minutes through a patterned chrome mask.  
13 After extensive rinsing with PBS the wafer was covered  
14 with a solution of 10mg ml<sup>-1</sup> bovine serum albumin and  
15 was exposed to light from a high pressure mercury  
16 vapour lamp for 15 minutes.

17  
18 (2) Assessment of protein patterning

19  
20 The wafer was covered with a solution of 10µg ml<sup>-1</sup> FITC  
21 labelled anti-rat IgG, for 60 minutes at ambient  
22 temperature. After washing in PBS and distilled water  
23 the sample was dried in a stream of nitrogen and  
24 examined using fluorescent microscopy. Areas of  
25 fluorescence were observed which matched the mask that  
26 had been used.

27  
28 Example 6

29  
30 Cell Guidance

31  
32 (1) Patterning of silicon surface

33  
34 A wafer of silicon dioxide was immersed in a 1%  
35 solution of 1,3-trimethoxysilylpropyl- ethylene diamine

1 in 95% ethanol 5% distilled water for 120 seconds.  
2 After removing the wafer from this solution it was  
3 rinsed briefly in 95% ethanol 5% distilled water before  
4 being heated at 120°C for 30 minutes. The wafer was  
5 immersed in a 2% solution of gluteraldehyde in PBS for  
6 15 minutes, and then in a solution of 40mM sodium  
7 cyanoborohydride, containing 0.2 mg ml<sup>-1</sup> Avidin D in PBS  
8 for 30 minutes at ambient temperature. After extensive  
9 rinsing with PBS the wafer was then incubated in .5ml  
10 of a 10 µg ml<sup>-1</sup> solution of long arm photobiotin in  
11 PBS for 20 minutes under dark room conditions. After  
12 extensive rinsing with PBS the wafer was covered with a  
13 sterile solution of 10 mg ml<sup>-1</sup> concanavalin A and  
14 exposed to light from a high pressure mercury vapour  
15 lamp for 15 minutes through a chrome mask patterned  
16 with a 12.5 µm grid . After extensive rinsing with PBS  
17 the wafer was covered with a sterile solution of 10mg  
18 ml<sup>-1</sup> bovine serum albumin and was exposed to light from  
19 a high pressure mercury vapour lamp for 15 minutes.

20

21 (2)

22

23 Snails were by placed in 25% Listerine for 5 minutes,  
24 and their brains were dissected out and incubated in 1  
25 mg ml<sup>-1</sup> Pronase at ambient temperature for 90 minutes.  
26 Individual cells were isolated and placed onto the  
27 patterned silica wafer in growth media consisting of  
28 33% (v/v) Gibco L-15, but with the CaCl<sub>2</sub> and MgCl<sub>2</sub>  
29 concentrations adjusted to 5.5mM and 2.43 mM  
30 respectively. The growth media also had additions of  
31 50 µg ml<sup>-1</sup> gentamycin and 0.2% glucose (w/v). The cells  
32 were incubated at 20°C for 7 days.

33

34 (3) Assessment of cell guidance.

35



1 The cells were examined under a microscope. Cell  
2 processes were to seen to run parallel with each other,  
3 and the distance between the processes was consistent  
4 with the patterning of the protein on the silicon  
5 dioxide.

6  
7 Example 7

8  
9 Multianalyte Sensor

10

11 In this example a multianalyte immunosensor for the  
12 quantitative determination of the human gonadotrophin  
13 hormones (follicle stimulating hormone and luteinising  
14 hormone) is produced. The assay is based upon the  
15 electrochemical detection of two horseradish peroxidase  
16 labelled antibodies using a ferrocene mediated system.  
17 Results obtained with the biosensor showed a good  
18 correlation with those obtained using an established  
19 clinical diagnostic technique based upon dissociation-  
20 enhanced lanthanide fluorometric immunoassay.

21

22 EXPERIMENTAL

23

24 Electrode Fabrication

25

26 Sensor arrays were produced on 10 cm diameter silicon  
27 wafers. Immobilisation of proteins was performed  
28 before the wafer was cut into individual devices, so  
29 that the preparation of all arrays was identical. Gold  
30 electrodes were prepared using standard  
31 photolithographic procedures. Both the electrodes and  
32 bonding pads were exposed whilst all other areas were  
33 electrically insulated using hardened photoresist.  
34 Ag/AgCl reference electrodes were prepared by  
35 electrosorbption of silver onto specified gold

1 electrodes from a solution of 0.1M AgNO<sub>3</sub> in 0.1M  
2 sulphuric acid with a silver anode (at a constant  
3 current of 0.4mA cm<sup>-2</sup> for 6 hours) followed by  
4 chloridisation in 0.1M HCl (0.4 mA cm<sup>-2</sup> for 30 minutes).  
5 The electrochemical behaviour of the fabricated  
6 electrodes was verified using cyclic voltammetry (-0.2  
7 to +0.75 V scanned at 20 mV s<sup>-1</sup>) in 0.2 mM ferrocene  
8 monocarboxylic acid (Sigma, Poole, England) containing  
9 50 mM Tris 50 mM KCl, pH 7.4. Results were compared  
10 with those obtained using a Bioanalytical Systems (BAS)  
11 gold working electrode and a BAS RE4 Ag/AgCl reference  
12 electrode (Biotech Instruments Ltd, Luton, England).  
13 Reproducibility of electrode arrays prepared in this  
14 manner, was assessed by measuring the  
15 chronoamperometric response (10 seconds at 0V, 120  
16 seconds at +650 mV) in the presence of 0.5 mM H<sub>2</sub>O<sub>2</sub> in 50  
17 mM sodium phosphate buffer containing 50 mM KCl, pH  
18 7.4. All experiments involving the fabrication and  
19 characterisation of electrodes were performed using an  
20 EG&G 273A potentiostat (EG&G, Sunninghill, England).

21

## 22 Antibody Immobilisation

23

24 The immobilisation procedure is outlined in Figure 3.  
25 Neutravidin™, a modified form of avidin (Pierce and  
26 Warriner, Chester, UK) was attached to the gold  
27 electrode surface using activation of a self-assembled  
28 thiol monolayer (in this case N-acetyl-l-cysteine  
29 (Sigma)) with a water soluble carbodiimide. Electrode  
30 arrays were first incubated in 2 mM N-acetyl-l-cysteine  
31 in 10 mM phosphate buffer (pH 7.0) for 120 minutes at  
32 ambient temperature, followed by 120 minutes incubation  
33 in 1% (w/v) 1-ethyl-3-(3-dimethylaminopropyl)-  
34 carbodiimide (EDC) (Sigma) in 10 mM phosphate buffer  
35 (pH 7.0). The modified gold sensor arrays were then

1 incubated in 100Ag ml<sup>-1</sup> Neutravidin in 10 mM phosphate  
2 buffer (pH 7.0) for 16 hours at 4°C. All subsequent  
3 stages of the immobilisation procedure were performed  
4 at ambient temperature. After washing in phosphate  
5 buffered saline (10 mM sodium phosphate, 137 mM NaCl,  
6 2.7 mM KCl), pH 7.4 (PBS), the electrodes were  
7 incubated first in 10 mg ml<sup>-1</sup> casein in PBS for 60  
8 minutes and then in 10 µg ml<sup>-1</sup> long arm photobiotin  
9 (Vector Laboratories, Peterborough, England) in PBS,  
10 for 20 minutes in the dark. All subsequent  
11 immobilisation stages were performed in a dark room.  
12 After washing in PBS, the wafer was covered with 10 Ag  
13 ml<sup>-1</sup> monoclonal anti-FSH (Biogenesis Ltd, Bournemouth,  
14 England, clone BIO-FSHB-003), and selected electrodes  
15 were exposed to light from a 100W HG-10101AF super high  
16 pressure mercury vapour lamp (Nikon, Tokyo, Japan) 185  
17 mm from the electrodes for 15 minutes (Irradiance = 9  
18 mW cm<sup>-2</sup>) using a suitable mask. It is important to note  
19 that light of wavelengths below 300 nm was removed by  
20 passing through a glass filter to prevent denaturation  
21 of proteins.

22

23 After washing in PBS, the wafer was covered with 10 µg  
24 ml<sup>-1</sup> monoclonal anti-LH (Biogenesis clone LH-007), and  
25 selected electrodes were exposed to light from the lamp  
26 for 15 minutes, prior to washing in PBS. The entire  
27 wafer was exposed to light from the lamp for 15 minutes  
28 in the presence of 10 mg ml<sup>-1</sup> casein in PBS, and washed  
29 in PBS.

30

### 31 Immunoassay procedure

32

33 The immunoassay, which was an enzyme linked  
34 immunosorbent assay (ELISA) based upon a "sandwich"  
35 format, was configured with immobilised "capture"

1 antibodies on the electrode surfaces such that the  
2 addition of a second enzyme labelled antibody was  
3 directed against a second epitopic site on the antigen.  
4 Sensors were incubated with 250  $\mu$ l of sample for 60  
5 minutes, washed thoroughly with PBS, and incubated in a  
6 mixture of 10  $\mu$ g  $\text{ml}^{-1}$  horseradish peroxidase (HRP)  
7 labelled anti-LH (Biogenesis clone BIO-FSHB-002) and 10  
8  $\mu$ g  $\text{ml}^{-1}$  HRP labelled anti-LH (Biogenesis clone LH-005)  
9 in PBS for 60 minutes at ambient temperature, before,  
10 finally, being washed in PBS. Simultaneous assessment  
11 of HRP activity at the FSH and LH sensor electrodes was  
12 performed chronoamperometrically using two  
13 Bioanalytical System CV-37 potentiostats (Biotech  
14 Instruments Ltd, Luton, England) and a Goerz SE120 dual  
15 channel chart recorder (Belmont Instruments, Glasgow,  
16 UK). Activity was determined at +150 mV vs Ag/AgCl by  
17 measuring the current produced after 20 seconds in the  
18 presence of 10 mM hydrogen peroxide and 0.2 mM  
19 ferrocene monocarboxylic acid in 50 mM phosphate buffer  
20 containing 50 mM KCl, pH 7.4. The response of the  
21 immunosensor to hormone concentration in a buffered  
22 aqueous solution was measured by preparation of a  
23 series of standards (0 - 100  $\text{U l}^{-1}$ ) of FSH and LH  
24 (Biogenesis) which covered the concentration range of  
25 clinical interest. The results obtained were  
26 subsequently used to construct a calibration curve for  
27 further experiments.

28  
29 The multi-analyte immunosensor was used to determine  
30 gonadotrophin concentrations in 10 serum samples from  
31 hospital outpatients. The analyses were performed on  
32 three separate occasions using a newly constructed  
33 calibration curve each time. The results obtained were  
34 compared with those obtained using an established  
35 DELFIA technique (see Lovgren et al Talanta 31: 909-916

1 (1984)). The samples examined covered the range of  
2 values typically seen in clinical laboratories.

3

#### 4 RESULTS AND DISCUSSION

5

##### 6 Patterning of Antibodies on Electrode Surfaces

7

8 Central to designing a multianalyte immunosensor is  
9 overcoming the problem of patterning of antibodies at  
10 discrete locations without encountering high levels of  
11 non-specific binding. In this example this difficulty  
12 has been overcome by using biological self-assembly of  
13 avidin and a biotin derivative, called photobiotin.  
14 The first stage of the patterning technique therefore  
15 involves immobilising either avidin or its microbial  
16 counterpart streptavidin onto a surface. Both of these  
17 are tetrameric proteins that specifically bind biotin  
18 with an association constant of  $10^{15} \text{ M}^{-1}$ . Photobiotin is  
19 bound to the avidin-modified surface to provide a light  
20 sensitive "addressable" surface onto which molecules  
21 can be "written" using an appropriate light source and  
22 a mask. Photobiotin contains an aryl azide group which  
23 is stable in the dark, but which, upon exposure to  
24 light (340-375 nm) forms a highly reactive aryl nitrene  
25 group. This will bind organic species present in the  
26 solution above the surface by a number of mechanisms  
27 including insertion into C-H or N-H bonds, and addition  
28 to C=C bonds. After immobilisation of the avidin, the  
29 surface was exposed to a solution of photobiotin which  
30 bound to the avidin-modified surface (Fig. 3a).  
31 Exposure of selected areas of this surface to light  
32 resulted in activation of the photobiotin molecule  
33 (Fig. 3b), so that antibodies present in the solution  
34 were immobilised onto the surface. To minimise the  
35 problem of non-specific binding of proteins at the

1     avidin modified surface, a modified form of avidin  
2     (Neutraavidin) which has low non-specific binding  
3     characteristics was used. Consequently, few protein  
4     molecules adhere to the surface non-specifically  
5     compared with the number that are bound by activated  
6     photobiotin. Any unbound material can be removed by  
7     washing. The patterning procedure can be repeated  
8     sequentially with a second protein (Fig. 3c) or with  
9     any number of proteins thereafter. In order to ensure  
10    that all unreacted photobiotin groups are  
11    "neutralised", the entire surface is exposed to light  
12    in the presence of a blocking molecule (eg casein or  
13    bovine serum albumin) (Fig. 3d).

#### 14 15    Characterisation of Electrodes

16  
17    The potentials at which oxidation and reduction peaks  
18    were evident upon cyclic voltammetry of ferrocene  
19    monocarboxylic acid for the fabricated electrodes were  
20    within 5 mV of those obtained when using standard BAS  
21    working and reference electrodes ( $E_{pa} = 355$  mV,  $E_{pc} = 296$   
22    mV). The intra-batch coefficient of variation for the  
23    responses of the electrode arrays to 0.5 mM  $H_2O_2$  was  
24    1.86% ( $n=20$ ), whilst the interbatch coefficient of  
25    variation was 2.43% ( $n=5$ ).

#### 26 27    Immunosensor Response

28  
29    The response of the sensor to FSH and LH in buffer was  
30    measured over the range 0 to 100  $U l^{-1}$ , Figures 4 and 5.  
31    When corrected for the specific activities of the  
32    hormone preparations, these ranges are equivalent to 0  
33    to 26  $ng\ l^{-1}$  and 0 to 18  $ng\ l^{-1}$  for FSH and LH  
34    respectively. Figure 4 demonstrates that the current  
35    at the FSH sensor is proportional to the FSH

1 concentration ( $2.1 \text{ nA / UI}^{-1}$  ( $8.0 \text{ nA/ngl}^{-1}$ )), and that the  
2 response of the LH sensor to FSH is negligible ( $0.07$   
3  $\text{nA/UI}^{-1}$  ( $0.38 \text{ nA/ngl}^{-1}$ )). Likewise, Figure 5  
4 demonstrates that the current produced by the LH sensor  
5 is proportional to the LH concentration ( $2.5 \text{ nA / UI}^{-1}$   
6 ( $13.6 \text{ nA / ng l}^{-1}$ )), and the response of the FSH sensor  
7 to LH is negligible ( $0.11 \text{ nA / UI}^{-1}$  ( $0.42 \text{ nA / ngl}^{-1}$ )).

8  
9 The response when no antigen is present is due to a  
10 number of factors, chief amongst these is the current  
11 resulting from electrochemical processes unrelated to  
12 the immunoassay (ie the background current obtained  
13 when there is no enzymic activity). The remainder of  
14 the current measured, when the antigen concentration is  
15 zero, is due either to non-specific binding or to  
16 diffusion of electroactive species between electrodes.

17  
18 Of the several causes of non-specific binding, the  
19 binding of an inappropriate antibody at a sensor site  
20 (eg anti-LH on a sensor for FSH) is of particular  
21 importance in a multianalyte immunosensor. This can  
22 occur for a number of reasons, such as binding through  
23 non-specific protein-protein interactions, hydrophobic  
24 interactions with non-polar surfaces, or electrostatic  
25 interactions between the protein and the surface, and  
26 results in an inappropriate antibody being able to bind  
27 its complimentary antigen and the enzyme labelled  
28 second antibody.

29  
30 Figures 6 and 7 show results for human serum samples  
31 obtained from the multianalyte sensor compared with  
32 those from an established DELFIA technique. This  
33 latter method uses lanthanides (which have a relatively  
34 long lived fluorescence) such as europium as  
35 fluorescent labels in immunoassays. The intensity of

1 the fluorescence is enhanced by dissociating the label  
2 from the immunocomplex prior to measurement. There is  
3 a very good correlation between the two methods, and  
4 close agreement between results at all concentrations  
5 for both FSH ( $[FSH]_{\text{IMMUNOSENSOR}} = 0.9756 [FSH]_{\text{DELPIA}} + 0.332$ ,  
6  $r^2 = 0.9990$ ) and, LH ( $[LH]_{\text{IMMUNOSENSOR}} = 0.9815 [LH]_{\text{DELPIA}} +$   
7  $0.125$ ,  $r^2 = 0.9996$ ).

8

## 9 Conclusion

10

11 The immobilisation procedure described enables the  
12 selective and specific patterning of multiple  
13 functional proteins with minimal non-specific binding.  
14 The process has the potential to be miniaturised with  
15 micrometre resolution and therefore may be used to  
16 produce multianalyte microsensors.

17

18 The applicability of this technique to multianalyte  
19 immunoassays has been demonstrated using determination  
20 of gonadotrophins as a model system. Although a sensor  
21 for measuring two analytes has been constructed, the  
22 technology that has been developed is compatible with  
23 the fabrication of a sensor for a greater number of  
24 analytes. The fabrication and immobilisation  
25 procedures used in this work would be compatible with  
26 manufacturing technology commonplace in the  
27 microelectronics industry. Additionally, there is no  
28 waste of expensive proteins such as monoclonal  
29 antibodies as non-immobilised excess protein can easily  
30 be recovered, and be reused.

31

## 32 Example 8

33

## 34 Patterning of Nucleic Acids

35



1 A SiO<sub>2</sub> wafer was immersed in 1% 1,3-trimethoxysilyl-  
2 propylethylene diamine in 95:5 (v/v) ethanol/distilled  
3 water for 120 seconds and briefly rinsed in 95:5 (v/v)  
4 ethanol/distilled water before heating at 120°C for 30  
5 minutes. The wafer was immersed in 2% gluteraldehyde  
6 in phosphate buffered saline (10 mM sodium phosphate,  
7 137 mM NaCl, 2.7 mM KCl, pH 7.4 (PBS)) for 15 minutes,  
8 and in 40 mM sodium cyanoborohydride, 0.2mg ml<sup>-1</sup>  
9 Neutravidin™ (Pierce & Warriner, Chester, UK) in PBS  
10 for 30 minutes. The SiO<sub>2</sub> substrate was washed in PBS  
11 after this and all subsequent steps. The avidin-  
12 modified wafer was incubated in 5 ml of 10 µg ml<sup>-1</sup> long  
13 arm photobiotin (Vector) in PBS for 20 minutes, this  
14 and all subsequent stages were performed under dark  
15 room conditions.  
16  
17 A solution of biotinylated DNA in PBS, was layered on  
18 to the SiO<sub>2</sub> wafer and a photolithographic mask with 3 µm  
19 lines (equal mark-space ratio) was placed on top. The  
20 sample was then exposed to light from a 100W high  
21 pressure mercury vapour lamp for 15 minutes (irradiance  
22 = 9 mW cm<sup>-2</sup>). Following exposure, the mask was removed  
23 and it and the wafer were thoroughly washed with PBS.  
24  
25 The sample was incubated in fluorescein isothiocyanate  
26 (FITC) labelled avidin for 2 hours, dried under a  
27 gentle stream of nitrogen and examined using  
28 fluorescence microscopy. A pattern corresponding to  
29 that of the photolithographic mask was observed.  
30  
31 Modifications and variations of the above described  
32 embodiments can be adopted without departing from the  
33 scope of the invention.

1     **Claims**

2

3     1.    A device having a surface, said surface having a  
4           ligand bound thereto in a pre-determined pattern,  
5           the binding of said ligand being determined by the  
6           irradiation or non-irradiation of a photosensitive  
7           binding moiety attached to said surface via a  
8           linking moiety.

9

10    2.    A device as claimed in Claim 1 wherein two or more  
11          ligands are bound to said surface.

12

13    3.    A device as claimed in either one of Claims 1 and  
14          2 which produces a measureable change.

15

16    4.    A device as claimed in any one of Claims 1 to 3  
17          wherein said linking moiety is avidin or a  
18          functional equivalent thereof.

19

20    5.    A device as claimed in any one of Claims 1 to 4  
21          wherein said photosensitive binding moiety is  
22          photobiotin or a functional derivative thereof.

23

24    6.    A device as claimed in any one of Claims 1 to 5  
25          wherein said ligand is a hormone, an enzyme or an  
26          immunoglobulin.

27

28    7.    A device as claimed in any one of Claims 1 to 6  
29          wherein substantially all of the photosensitive  
30          binding moiety not bound to ligand is bound to a  
31          blocking protein.

32

33    8.    A device as claimed in any one of Claims 1 to 7  
34          wherein the surface is silicon, silicon nitride,  
35          silicon dioxide, glass, quartz, metals, metal

1 oxides, polymers and/or mixtures thereof.

2

3 9. A device as claimed in any one of Claims 1 to 8  
4 for use in a multi-analyte sensor, in molecular  
5 electronics, in binding nucleotides, in  
6 directional propagation of cells, and/or in  
7 alteration of cell behaviour.

8

9 10. Use of a device as claimed in any one of Claims 1  
10 to 8 in a multi-analyte sensor.

11

12 11. Use as claimed in Claim 10 in a multi-analyte  
13 immunosensor.

14

15 12. Use of a device as claimed in any one of Claims 1  
16 to 8 in molecular electronics.

17

18 13. Use of a device as claimed in any one of Claims 1  
19 to 8 in directional propagation of cells.

20

21 14. Use of a device as claimed in any one of Claims 1  
22 to 8 in the alteration of cell behaviour.

23

24 15. An immunosensor comprising a device as claimed in  
25 any one of Claims 1 to 8.

26

27 16. A multi-analyte immunosensor comprising a device  
28 as claimed in any one of Claims 1 to 8.

29

30 17. An electronics device comprising a device as  
31 claimed in any one of Claims 1 to 8.

32

33 18. Cells obtained by propagation using a device as  
34 claimed in any one of Claims 1 to 8.

35

- 1 19. A process for forming a surface having a ligand  
2 bound thereto in a pre-determined pattern, said  
3 process comprising the following steps:  
4
- 5 i) binding a linking moiety to a coated or uncoated  
6 surface;  
7
- 8 ii) binding a photosensitive binding moiety to said  
9 linking moiety;  
10
- 11 iii) selectively exposing said photosensitive binding  
12 moiety to irradiation in a pre-determined pattern;  
13
- 14 iv) exposing said binding moiety to said ligand and  
15 allowing the ligand to bind to said binding moiety  
16 in accordance with the irradiation exposure;  
17
- 18 v) optionally removing excess ligand by washing; and  
19
- 20 vi) optionally exposing said ligand to a further  
21 molecule capable of binding thereto.  
22
- 23 20. A process as claimed in Claim 19 wherein steps  
24 iii) and iv) are repeated at least once to bind a  
25 second ligand to said surface in a pre-determined  
26 pattern.  
27
- 28 21. A process as claimed in either one of Claims 19  
29 and 20 wherein substantially all of the  
30 photosensitive binding moiety not bound to ligand  
31 is subsequently bound to a blocking moiety.  
32
- 33 22. A process as claimed in any one of Claims 19 to 21  
34 wherein selective irradiation or non-irradiation  
35 of said photosensitive binding moiety is achieved

1           by use of a mask.


2

3       23.   Use of a device as claimed in any one of Claims 1  
4           to 8 for diagnosis.

5


6       24.   Use of a device as claimed in any one of Claims 1  
7           to 8 for binding nucleotides.

1/7


Figure 1

SUBSTITUTE SHEET (RULE 26)

2/7

Figure 2

3/7

Figure 3

= avidin

= 1st protein

= photobiotin


= 2nd protein

= blocking species

SUBSTITUTE SHEET (RULE 26)




4/7


Figure 4

SUBSTITUTE SHEET (RULE 26)

5/7


Figure 5

6/7

Figure 6

SUBSTITUTE SHEET (RULE 26)

7/7

Figure 7

SUBSTITUTE SHEET (RULE 26)

## INTERNATIONAL SEARCH REPORT

International Application No

PCT/GB 94/02680

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 G01N33/543 G01N33/547 C12Q1/68

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 G01N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	JOURNAL OF IMMUNOLOGICAL METHODS., vol.132, 1990, NEW YORK US pages 91 - 101 W. EMLÉN ET AL. 'A NEW ELISA FOR THE DETECTION OF DOUBLE-STRANDED DNA ANTIBODIES.' see the whole document ---	1-24
Y	EP,A,0 127 438 (NATIONAL RESEARCH DEVELOPMENT CO.) 5 December 1984 cited in the application see the whole document & GB,A,2 141 544 ---	1-24
A	WO,A,91 07087 (AFFYMAX TECHNOLOGIES, N. V.) 30 May 1991 --- -/--	

☒ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.

## \* Special categories of cited documents :

- \* "A" document defining the general state of the art which is not considered to be of particular relevance
- \* "E" earlier document but published on or after the international filing date
- \* "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \* "O" document referring to an oral disclosure, use, exhibition or other means
- \* "P" document published prior to the international filing date but later than the priority date claimed

\* "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

\* "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

\* "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

\* "&" document member of the same patent family

Date of the actual completion of the international search

19 April 1995

Date of mailing of the international search report

10.05.95

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax (+31-70) 340-3016

Authorized officer

Cartagena y Abella,P

## INTERNATIONAL SEARCH REPORT

International Application No  
PCT/GB 94/02680

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	NUCLEIC ACIDS RESEARCH, vol.13, no.3, 1985, ARLINGTON, VIRGINIA US pages 745 - 761 A.C. FORSTER ET AL. 'NON-RADIOACTIVE HYBRIDIZATION PROBES PREPARED BY THE CHEMICAL LABELLING OF DNA AND RNA WITH A NOVEL REAGENT, PHOTOBIOITIN.' -----	

## INTERNATIONAL SEARCH REPORT

International Application No

PCT/GB 94/02680

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP-A-0127438	05-12-84	CA-A- 1229883	01-12-87
		DE-A- 3468146	28-01-88
		GB-A, B 2141544	19-12-84
		JP-B- 6050316	29-06-94
		JP-A- 59225343	18-12-84
		US-A- 4562157	31-12-85
-----			
GB-A-2141544	19-12-84	CA-A- 1229883	01-12-87
		DE-A- 3468146	28-01-88
		EP-A, B 0127438	05-12-84
		JP-B- 6050316	29-06-94
		JP-A- 59225343	18-12-84
		US-A- 4562157	31-12-85
-----			
WO-A-9107087	30-05-91	AU-A- 6886791	13-06-91
		EP-A- 0502060	09-09-92
		JP-T- 5501611	25-03-93
		US-A- 5252743	12-10-93
-----			